Van Zwieten P A, De Jonge A, Timmermans P B
Pharm Weekbl Sci. 1983 Oct 21;5(5):197-204. doi: 10.1007/BF02332943.
Inhibitors of the angiotensin I converting enzyme (captopril, enalapril) offer a new principle in the drug treatment of hypertension and congestive heart failure. The present survey deals with the mode of action of the converting enzyme inhibitors, including possible interference with the renin-angiotensin systems in the kidney, the vascular wall and the brain, with the kallikrein--bradykinin system and with the sympathetic nervous system, at both pre- and postjunctional sites. Furthermore, the haemodynamic pattern as well as the therapeutic applications are discussed, including the most important side-effects, contra-indications, interactions and clinical pharmacokinetic properties.
血管紧张素I转换酶抑制剂（卡托普利、依那普利）为高血压和充血性心力衰竭的药物治疗提供了新的原理。本综述探讨了转换酶抑制剂的作用方式，包括其在肾脏、血管壁和大脑中对肾素 - 血管紧张素系统、激肽释放酶 - 缓激肽系统以及交感神经系统在节前和节后位点可能产生的干扰。此外，还讨论了血流动力学模式以及治疗应用，包括最重要的副作用、禁忌症、相互作用和临床药代动力学特性。
